HLA mismatch combinations associated with decreased risk of relapse: Implications for the molecular mechanism

Blood

Volumn 113, Issue 12, 2009, Pages 2851-2858

  Kawase, Takakazu ^a   Matsuo, Keitaro ^a   Kashiwase, Koichi ^b   Inoko, Hidetoshi ^c   Saji, Hiroh ^d   Ogawa, Seishi ^e   Kato, Shunichi ^c   Sasazuki, Takehiko ^f   Kodera, Yoshihisa ^g   Morishima, Yasuo ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b Tokyo Red Cross Blood Center   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Japanese Red Cross Kanto Koshinetsu Block Blood Center   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^g JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; HLA DPB1 ANTIGEN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER RELAPSE; CANCER RISK; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; CROSS PRESENTATION; DONOR; DONOR SELECTION; FEMALE; GENE IDENTIFICATION; GENE LOCUS; GENETIC ASSOCIATION; GENOTYPE; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL;

EID: 63849288804     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-08-171934     Document Type: Article

References (29)

1. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068-1073.
2. Gale RP, Horowitz MM. Graft-versus-leukemia in bone marrow transplantation: the Advisory Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1990; 6(suppl 1):94-97.
3. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555-562.
4. Carella AM, Beltrami G, Corsetti MT, et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet. 2005;366:318-320.
5. Bregni M, Dodero A, Peccatori J, et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood. 2002;99:4234-4236.
6. Ueno NT, Cheng YC, Rondon G, et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood. 2003;102:3829-3836.
7. Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer. 2004;4:371-380.
8. Kawase T, Morishima Y, Matsuo K, et al. High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood. 2007;110:2235-2241.
9. Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor: Japan Marrow Donor Program. N Engl J Med. 1998;339:1177-1185.
10. European Molecular Biology Laboratory-European Bioinformatics Institute. IMGT/HLA database. http://www.ebi.ac.uk/imgt/hla/. Accessed May 1, 2008.
11. GooleyTA, Leisenring W, CrowleyJ, StorerBE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706.
12. Coviello V, Boffess M. Cumulative incidence estimation in the presence of compiting risks. Stata J. 2004;4:103-112.
13. Cox DR. Regression models and life-tables. J R Stat Soc Ser B. 1972;34:187-220.
14. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-497.
15. Efron B. Bootstrap methods: another look at the jackknife. Ann Stat. 1979;7:1-26. 16. Manly BFJ. Randomization, Bootstrap and Monte Carlo Methods in Biology. London, United Kingdom: Chapman and Hall; 1997.
16. Shaw BE, GooleyTA, Malkki M, et al. The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. Blood. 2007;110: 4560-4566.
17. Morishima Y, Yabe T, Matsuo K, et al. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor. Biol Blood Marrow Transplant. 2007;13:315-328.
18. Weichold FF, Jiang YZ, Dunn DE, et al. Regulation of a graft-versus-leukemia effect by major histocompatibility complex class II molecules on leukemia cells: HLA-DR1 expression renders K562 cell tumors resistant to adoptively transferred lymphocytes in severe combined immunodeficiency mice/nonobese diabetic mice. Blood. 1997;90:4553-4558.
19. Gribben JG, Guinan EC, Boussiotis VA, et al. Complete blockade of B7 family-mediated co-stimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. Blood. 1996;87:4887-4893.
20. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Gray GS, Vallera DA. Coblockade of the LFA1: ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graftversus-host disease induced by fully major histocompatibility complex-disparate donor grafts. Blood. 1995;85:2607-2618.
21. Hogan KT, Clayberger C, Bernhard EJ, et al. Identification by site-directed mutagenesis of amino acid residues contributing to serologic and CTL-defined epitope differences between HLA-A2.1 and HLA- A2.3. J Immunol. 1988;141:2519-2525.
22. Mattson DH, Shimojo N, Cowan EP, et al. Differential effects of amino acid substitutions in the beta-sheet floor and alpha-2 helix of HLA-A2 on recognition by alloreactive viral peptide-specific cytotoxic T lymphocytes. J Immunol. 1989;143: 1101-1107.
23. Shimojo N, Cowan EP, Engelhard VH, Maloy WL Coligan JE, Biddison WE. A single amino acid substitution in HLA-A2 can alter the selection of the cytotoxic T lymphocyte repertoire that responds to influenza virus matrix peptide 55-73. J Immunol. 1989;143:558-564.
24. Tynan FE, Elhassen D, Purcell AW, et al. The immunogenicity of a viral cytotoxic T cell epitope is controlled by its MHC-bound conformation. J Exp Med. 2005;202:1249-1260.
25. Macdonald WA, Purcell AW, Mifsud NA, et al. A naturally selected dimorphism within the HLA- B44 supertype alters class I structure, peptide repertoire, and T cell recognition. J Exp Med. 2003;198:679-691.
26. Shaw BE, Marsh SGE, Mayor NP, Madrigal JA. Matching status at amino acid positions 57 and 65 of the HLA-DPB1 beta chain determines outcome in recipients of unrelated donor haematopoietic stem cell transplants [abstract]. Blood. 2004;104:Abstract 827.
27. Steven GE, Peter P, Linda DB. The HLA Facts Book. London, United Kingdom: Academic Press; 2000.
28. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097-2100.
29. Yabe T, Matsuo K, Hirayasu K, et al. Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR ligand-mismatched T cell-replete unrelated bone marrow transplantation. Biol Blood Marrow Transplant. 2008;14:75-87.